shreshtha shah

Principal Scientist at ImmunoACT

[ImmunoACT @ActImmuno]

It all began with a vision to make cutting-edge therapies accessible to every patient who needs them.

Today, #NexCAR19 stands as a symbol of that vision realized, a humanized, single-dose CAR-T therapy with ~98% manufacturing success and up to 90% cost reduction for patients with blood cancer.

2 years. Over 400 lives transformed. Many more to go. Every patient’s recovery fuels our purpose and our promise to do more.

#NexCAR19 #2YearsStrong #CARTherapy #TransformingLives #HealthcareInnovation #MadeInIndia #ImmunoACT

@purwarrahul2 @atharvak03 @shreshthashah97

[ImmunoACT @ActImmuno]

Our Founder, Prof. Rahul Purwar , will be representing ImmunoACT at the Fifth Innovative Therapies Days 2025: An International Symposium, taking place in Besancon, France.
📅 October 9–10, 2025
📍 Kursaal, Besancon, France

Prof. Purwar will be sharing the inspiring "Journey of India’s First Indigenous CAR-T Therapy", highlighting scientific innovation and the progress towards accessible, affordable cell and gene therapies from India.
📩 To connect with us during the event, reach out to [email protected]

#InnovativeTherapiesDays #CARTcellTherapy #ImmunoACT #NexCAR19 #CellTherapy #GeneTherapy #IndianBiotech #GlobalHealth #BiotechInnovation

[ImmunoACT @ActImmuno]

At #ImmunoACT, we believe that effective counselling is the first step in a patient’s CAR-T journey - helping families move forward with clarity, confidence, and hope.

In this expert talk, Dr. Esha Kaul (Director, Haematology, Hemato-Oncology & Bone Marrow Transplant, Max Healthcare ) shares her perspective on the evolving approach to counseling patients for #NexCAR19.

Watch now to understand how experience has shaped better counselling for CAR-T patients and how it is transforming cancer care in India.
🔗Click the link to watch the complete video: https://t.co/3TYP7RhpnC

#CARTCellTherapy #NexCAR19 #CancerCare #ImmunoACT #BloodCancer #LeukemiaTreatment #Immunotherapy #IndianInnovation

@purwarrahul2 @shreshthashah97 @sarya3 @atharvak03 @EshaKaul1 @MaxHealthcare

[ImmunoACT @ActImmuno]

𝗪𝗲'𝘃𝗲 𝗦𝗲𝗰𝘂𝗿𝗲𝗱 𝗮 𝗨𝗦 𝗣𝗮𝘁𝗲𝗻𝘁 𝗳𝗼𝗿 𝗡𝗲𝘅𝗖𝗔𝗥𝟭𝟵™ (𝘁𝗮𝗹𝗶𝗰𝗮𝗯𝘁𝗮𝗴𝗲𝗻𝗲 𝗮𝘂𝘁𝗼𝗹𝗲𝘂𝗰𝗲𝗹), 𝘁𝗵𝗲 𝗪𝗼𝗿𝗹𝗱’𝘀 𝗙𝗶𝗿𝘀𝘁 𝗛𝘂𝗺𝗮𝗻𝗶𝘀𝗲𝗱 𝗖𝗔𝗥-𝗧 𝗖𝗲𝗹𝗹 𝗧𝗵𝗲𝗿𝗮𝗽𝘆 𝗳𝗿𝗼𝗺 𝗜𝗻𝗱𝗶𝗮!

At #ImmunoACT, India’s homegrown pioneer in cell and gene therapy, we are proud to announce that we have received a United States patent for #NexCAR19, our novel humanized CAR-T cell therapy.

This milestone marks a powerful validation of NexCAR19’s scientific rigor and commercial potential - and reinforces our position as a leading innovator in global cancer care.

With #NexCAR19, we have become the first company globally to develop and commercialize a humanised CAR-T cell therapy, bringing transformative treatment options to patients with relapsed and refractory B-cell cancers. now infused in over 400 patients successfully.

This patent further strengthens our IP portoflio and paves the way for global partnerships, scale-up, and international expansion. Backed by cutting-edge science, indigenous development, and a bold global vision, we are shaping a new era for advanced therapeutics - from India to the world.

#NexCAR19 #CAR_TCellTherapy #USPatent #MadeInIndia #GlobalScience #BiotechInnovation #ImmunoACT

@purwarrahul2 @atharvak03 @shreshthashah97 @iitbombay @ACTREC_TMC @TataMemorial

[ImmunoACT @ActImmuno]

𝗙𝗿𝗼𝗺 𝘃𝗶𝘀𝗶𝗼𝗻 𝘁𝗼 𝘃𝗮𝗹𝗶𝗱𝗮𝘁𝗶𝗼𝗻 - our journey in pioneering CAR-T in India is now a profitable one. Grateful for the persistence, passion, and purpose that drives our mission to make advanced therapies accessible.

🔗https://t.co/0esKwRRVRh

#CAR_TCellTherapy #MadeInIndia #BiotechStartups #HealthcareInnovation #ImmunoACT #CancerCare #StartupMilestone

@purwarrahul2 @sarya3 @Atharvakarulkar @shreshthashah97 @iitbombay @TataMemorial @ACTREC_TMC

[ImmunoACT @ActImmuno]

We are happy to share that Dr. Sushant Kumar, Senior Scientist at #ImmunoACT, recently delivered an inspiring lecture at @iitbombay to the National-level winners of Vidyarthi Vigyan Manthan (VVM) - India’s premier science talent program for VI-XI school students.
His talk, titled “Introduction to Gene Therapy: The Story of India’s First Approved Gene Therapy,” aimed to simplify the complex science behind gene therapy and share the incredible journey of #NexCAR19 - India’s first approved gene therapy, developed indigenously by IIT Bombay, @TataMemorial , and @ActImmuno .

Key highlights from the session:
✅ Basics of genes and gene therapy
✅ How gene therapy works - explained through simple, relatable examples
✅ The story behind NexCAR19, a groundbreaking CAR-T cell therapy developed in India
✅ Future of gene therapy, including innovative technologies like in vivo CAR-T therapy

The students were highly engaged, asking insightful questions about genetic technologies, immune cells, and the future of medical science.
At ImmunoACT, we strongly believe in nurturing scientific curiosity among young minds. We are committed to driving accessible, innovative therapies and sharing knowledge that can inspire future scientists and innovators.

#ImmunoACT #GeneTherapy #VVM #NexCAR19 #STEMEducation #CAR_T #Innovation #ScienceEducation #IITBombay #YoungScientists #India

[ImmunoACT @ActImmuno]

At ImmunoACT, we believe CAR-T cell therapy is more than just medicine - it’s a personalized revolution in the fight against cancer.

In this exclusive video, our medical expert Dr. @SameerMelinkeri from Deenanath Mangeshkar Hospital and Research Center (@DMHospitalPune) simplifies what patients and caregivers need to know about CAR-T therapy - from who’s eligible to how to prepare, what to expect during treatment, and how it can transform outcomes.

Watch now to get clear, science-backed insights into India’s very own CAR-T innovation: #NexCAR19

🔗 Click the link to watch complete video: https://t.co/30HKGDX6P5

#CARTCellTherapy #NexCAR19 #CancerCare #ImmunoACT #BloodCancer #LeukemiaTreatment #Immunotherapy #IndianInnovation

@purwarrahul2 @sarya3 @AtharvaKarulka1 @shreshthashah97 @TataMemorial @iitbombay @ACTREC_TMC

[ImmunoACT @ActImmuno]

Our Founder, Prof. Rahul Purwar (@purwarrahul2), will be attending the 𝗘𝗛𝗔 𝟮𝟬𝟮𝟱 𝗖𝗼𝗻𝗴𝗿𝗲𝘀𝘀, a premier gathering in the field of hematology, taking place in Milan, Italy.

📅 June 12–15, 2025
📍 Milan, Italy

Prof. Purwar will be present to connect with global experts, explore cutting-edge research, and discuss about NexCAR19 - India’s first indigenous CAR-T cell therapy.

📩 To schedule a meeting, write to us at [email protected]

#EHA2025 #CAR_TcellTherapy #Hematology #AdvancedTherapies #ImmunoACT #NexCAR19 #CancerTreatment #CellTherapy #GeneTherapy #IndianBiotech

[ImmunoACT @ActImmuno]

𝗪𝗲’𝗿𝗲 𝗟𝗶𝘃𝗲! 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝗹𝗹-𝗡𝗲𝘄 𝗜𝗺𝗺𝘂𝗻𝗼𝗔𝗖𝗧 𝗪𝗲𝗯𝘀𝗶𝘁𝗲

Our new website is here - with a fresh design, smoother navigation, and everything you need to know about our CAR-T journey. Explore our product pipeline, learn more about #NexCAR19, meet the team driving our science, and stay updated - all in one place.

🌐 Visit us: https://t.co/igiwEDjSxl

#ImmunoACT #WebsiteLaunch #CARTCellTherapy #NexCAR19

@purwarrahul2 @atharvak03 @shreshthashah97

[ImmunoACT @ActImmuno]

𝗪𝗼𝗿𝗹𝗱 𝗕𝗹𝗼𝗼𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆 𝗦𝗲𝗿𝗶𝗲𝘀 | 𝗗𝗮𝘆 𝟯 – 𝗔 𝗡𝗲𝘄 𝗘𝗿𝗮 𝗼𝗳 𝗛𝗼𝗽𝗲

Not all battles are visible - but every one of them deserves a powerful ally.
For patients with blood cancers who’ve exhausted conventional treatments, there’s now a breakthrough made in India: #NexCAR19, our indigenous CAR T Cell Therapy.
Built on the strength of science and compassion, NexCAR19 is helping rewrite stories of relapse into stories of recovery.
This World Blood Cancer Day, let’s amplify what matters - access to innovation, hope for every patient, and the power of homegrown breakthroughs.
Because behind every treatment, there’s a life waiting for a second chance.

#WorldBloodCancerDay #NexCAR19 #ImmunoACT #CARTcellTherapy #BloodCancerAwareness #MadeInIndia #InnovationForIndia #HopeInHealthcare

[ImmunoACT @ActImmuno]

𝗪𝗼𝗿𝗹𝗱 𝗕𝗹𝗼𝗼𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆 𝗦𝗲𝗿𝗶𝗲𝘀 | 𝗗𝗮𝘆 𝟮 – 𝗟𝗲𝘁’𝘀 𝗧𝗮𝗹𝗸 𝗔𝗯𝗼𝘂𝘁 𝗟𝗲𝘂𝗸𝗲𝗺𝗶𝗮

Beyond the diagnosis is a childhood on pause, and a future worth fighting for. Yet, Acute Lymphoblastic Leukemia (ALL) accounts for 25% of all childhood cancers in India. Even after treatment, 15% of children relapse, often with limited options left.

At ImmunoACT, we believe every child deserves a second chance. That’s why we developed NexCAR19 - India’s own CAR-T cell therapy. It uses a patient’s own T-cells to fight cancer, offering a 73% complete response rate, even in tough, relapsed cases.

This therapy isn’t just effective - it’s personalized, proven for both kids and adults, and brings the promise of long-term remission, even after multiple relapses.

This #WorldBloodCancerDay, let’s stand together for children and families fighting leukemia. Let’s raise awareness and support innovations that bring real hope - right here at home.

#LeukemiaAwareness #ChildhoodCancer #NexCAR19 #CAR_TcellTherapy #ImmunoACT #WorldBloodCancerDay #HopeForHealing #MadeInIndia #HealthcareInnovation

[ImmunoACT @ActImmuno]

𝗪𝗼𝗿𝗹𝗱 𝗕𝗹𝗼𝗼𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆 𝗦𝗲𝗿𝗶𝗲𝘀 | 𝗗𝗮𝘆 𝟭 – 𝗟𝗲𝘁’𝘀 𝗧𝗮𝗹𝗸 𝗔𝗯𝗼𝘂𝘁 𝗟𝘆𝗺𝗽𝗵𝗼𝗺𝗮
Behind every cancer statistic is a person, a family, a story.

In India, over 𝟯𝟵,𝟬𝟬𝟬 people are diagnosed with lymphoma each year - and 𝟮𝟮,𝟬𝟬𝟬 don’t make it. Many of them never knew the signs: constant fatigue, night sweats, or unexplained weight loss. These early symptoms are easy to miss, but the cost of delay can be life changing.

At ImmunoACT, we believe that no one should lose a loved one to a treatable disease. That’s why we developed #NexCAR19 - India’s very own CAR-T cell therapy.

With a 73% response rate, minimal side effects, and shorter hospital stays, NexCAR19 is not just a medical breakthrough - it’s a hopeful, accessible solution for those who need it most. Most importantly, it’s the world’s most affordable CAR-T therapy, built for our people, right here at home.

This #WorldBloodCancerDay, let’s come together - to spread awareness, encourage early detection, and champion homegrown innovations that can change lives.

Stay with us as we share real facts, and solutions leading up to May 28.

#LymphomaAwareness #CAR_TcellTherapy #NexCAR19 #ImmunoACT #WorldBloodCancerDay #CancerCareIndia #InnovationForIndia #HopeInHealthcare

[ImmunoACT @ActImmuno]

On 𝗪𝗼𝗿𝗹𝗱 𝗕𝗹𝗼𝗼𝗱 𝗖𝗮𝗻𝗰𝗲𝗿 𝗗𝗮𝘆, we are hosting a special webinar featuring two renowned experts in hematology.
Dr. Rahul Bhargava, Fortis Hospital will speak on strategies to improve access to CAR-T cell therapy in India. This will be followed by Dr Kunal Goyal (Kokilaben Hospital, Navi Mumbai), who will share real-world evidence and case insights on CAR-T treatment for lymphomas.
The session will conclude with a brief Q&A. Join us as we spotlight the growing impact of CAR-T therapy in advancing blood cancer treatment.

🗓️ Wednesday, May 28, 2025
⏲️ 7:00 PM - 8:30 PM IST
🔗https://t.co/5mu6Y7QgMW

#CARTCellTherapy #WorldBloodCancerDay #BloodCancerAwareness #CellTherapy #Lymphoma #Hematology #Webinar

[ImmunoACT @ActImmuno]

At #CARTSummit2025, the session titled “Bridging the Gap - Role of NGOs and CSR in Providing Intent-to-Cure Solutions for Cancer Care” brought together experts from healthcare and the development sector to address access challenges in cancer treatment. Moderated by Ms. Sunita Rao, the panel included Ms. Poyni Bhatt, Mr. Neerad Trivedi, Mr. Ravi Vantaram, Dr. Suja Nair, and Dr. Haresh Kumar Gupta.

The discussion highlighted the funding limitations NGOs face, especially for advanced therapies like CAR-T, as CSR funds are often directed to hospitals. Panelists emphasized the critical role of NGOs in patient navigation and education, and the need for stronger collaboration between hospitals, NGOs, and CSR partners.

A key challenge discussed was the demand for short-term impact metrics by CSR organizations - often at odds with the long-term nature of cancer care. The panel also noted that better data transparency, especially in childhood cancer outcomes, could help attract sustained CSR support. The session closed with a call for multi-year CSR commitments and strategic partnerships to make curative cancer therapies more accessible across India.

#ImmunoACT #NexCAR19 #CARTSummit2025 #NGOCollaboration #MadeInIndiaScience #ConferenceHighlights

[ImmunoACT @ActImmuno]

Excited to see our founder and @iitbombay Prof. Rahul Purwar (@purwarrahul2 ) share the incredible journey of India’s first homegrown CAR-T cell therapy tomorrow at @THSTIFaridabad!

#NationalTechnologyDay #MakeInIndia #CARTcell #ImmunoACT #NexCAR19

[ImmunoACT @ActImmuno]

At #CARTSummit2025, Ms. Shalini Jatia, Officer in Charge at ImPaCCT Foundation, Tata Memorial Centre, led a powerful session titled “Patient Journey: Learning the Patient's Journey in the Patient's Own Voice.”

The session brought to the stage eight CAR-T therapy recipients who shared deeply personal stories of resilience, hope, and recovery. From professionals like Dr. Preeti Arora to young survivors like Master Rajdeep Dubey, each voice underscored the human impact behind this cutting-edge treatment.

Ms. Jatia’s thoughtful moderation highlighted the courage of patients and their families, reminding us that behind every breakthrough is a life transformed. This session was a heartfelt call to make CAR-T therapy more accessible and patient-centered.

#ImmunoACT #NexCAR19 #CARTSummit2025 #MadeInIndiaScience #ConferenceHighlights

[ImmunoACT @ActImmuno]

At #CARTSummit2025, Mr. Shirish Arya, our Co-founder and Director of Corporate Strategy and Business Development at ImmunoACT, delivered an insightful session titled “Innovating for Impact: Building Scalable, Affordable, and Accessible CAR-T Cell Therapy in India.”

He highlighted ImmunoACT’s unique approach to developing indigenous CAR-T technology - rooted in academic excellence and mission-driven commercialization. Mr. Arya emphasized the importance of frugal innovation, ensuring therapies remain cost-effective without compromising on quality or global standards.

He also addressed the critical role of public-private partnerships, robust supply chain infrastructure, and talent development in scaling advanced therapies like CAR-T in emerging markets.

His session offered a compelling perspective on building a sustainable innovation ecosystem - one that positions India to lead in making cell and gene therapies accessible and impactful for patients across all socioeconomic backgrounds.

#ImmunoACT #NexCAR19 #CARTSummit2025 #MadeInIndiaScience #ConferenceHighlights

[ImmunoACT @ActImmuno]

Durable, deep, and life-changing – Our CAR-T cell therapy (NexCAR19) continues to demonstrate real-world impact. We’re proud to see our first patient at Aster MIMS still in remission months after treatment. Durability isn't just a clinical metric, it's a second chance at life. Grateful to partner with Dr. Sudeep Vaniyath and the dedicated team at Aster MIMS Calicut in bringing renewed hope to patients who had exhausted all other options.

#CARTCellTherapy #NexCAR19 #AsterMIMS #CancerTreatment #ImmunoACT

[ImmunoACT @ActImmuno]

At #CARTSummit2025, Dr. Rajeev Raghuvanshi, Drugs Controller General of India (DCGI), Central Drugs Standard Control Organization (CDSCO), delivered a forward-looking session titled “Advanced Healthcare: Can India Lead the Way for Cell and Gene Therapy in the Next Decade?”

He emphasized India’s growing capability to become self-reliant in advanced therapeutics, highlighting the need for strong regulatory frameworks, domestic innovation, and affordable manufacturing.

Dr. Raghuvanshi noted that CDSCO is actively working to streamline regulatory pathways for cell and gene therapy, aiming to balance patient safety with accelerated access to cutting-edge treatments. He also underscored the importance of policy support, industry collaboration, and scalable infrastructure in enabling equitable access to these therapies.

His session reflected a bold vision - positioning India as a global leader in delivering safe, affordable, and transformative healthcare solutions through innovation.

#ImmunoACT #NexCAR19 #CARTSummit2025 #MadeInIndiaScience #ConferenceHighlights #CancerTreatment

[ImmunoACT @ActImmuno]

We’re proud to share that our Co-founder and Head of Scientific Programs, Dr. Atharva Karulkar, paneled a session at the World Health Summit Regional Meeting 2025 in New Delhi.
Dr. Karulkar was invited to share his insights during a thought-provoking session titled "How to Broaden Access to Gene Therapy in the Global South", moderated by Ben Johnson, Chief Editor of Nature Health. This important discussion brought together experts from academia, industry, and civil society to address the critical need for affordable and accessible gene therapies in low- and middle-income countries.
Dr. Karulkar highlighted the journey of #NexCAR19, India’s first indigenous CAR-T cell therapy, and emphasized the need for collaborative, cost-effective innovation to overcome the economic and infrastructural barriers surrounding advanced therapies. His remarks underscored the importance of investing in homegrown solutions and scientific talent to ensure equitable access to life-saving treatments like gene and cell therapies.